Baxter rolling out BioStat 1000 real-time on-line hemodialysis monitor.
This article was originally published in The Gray Sheet
Executive SummaryBAXTER ROLLING OUT BIOSTAT 1000 ON-LINE HEMODIALYSIS MONITOR at approximately $11,000 per unit in the U.S., the firm announced June 22. The real-time monitoring system, cleared via 510(k) May 8, "facilitates individualized prescription and nutritional therapy for patients on hemodialysis and reduces the need for additional blood samples and laboratory analyses," the firm claims.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.